Quarterly Result8 Aug 2025, 09:43 am
Sai Life Sciences Reports 77% Revenue Growth YoY in Q1FY26, With Revenue at 496 Cr, EBITDA at 125 Cr, and Net Profit at 60 Cr
AI Summary
Sai Life Sciences Limited, a Contract Research, Development and Manufacturing Organization (CRDMO), announced its financial results for the first quarter and Fiscal year 2026. The company reported a 77% year-over-year (YoY) increase in revenue from operations, which stood at 496 crores for Q1FY26. The EBITDA stood at 125 crores, marking a 303% increase. The company also invested 134 crores in capital expenditure during Q1FY26. Business highlights include the commencement of commercial operations at Bidar Unit IV (PB-11 Phase II), the inauguration of the Peptide Research Center at Hyderabad R&D campus, and the construction of a new Medicinal Chemistry block with 200 fume hood capacity.
Key Highlights
- Revenue from Operations was 496 Cr for Q1FY26, a 77% YoY increase
- EBITDA stood at 125 Cr for Q1FY26, a 303% YoY increase
- Invested 134 crores in capital expenditure during Q1FY26
- Commenced commercial operations at Bidar Unit IV (PB-11 Phase II)
- Inaugurated Peptide Research Center at Hyderabad R&D campus